Who we are

1. The company

Oriskami SAS is a French simplified joint-stock company (SAS), incorporated in 2021 in Saint-Grégoire (Brittany). The Tribunal de commerce de Rennes registered it under SIREN 892 745 969 (VAT FR19892745969, NAF 7219Z). The registered office sits at Parc EDONIA – Bâtiment M, rue des Îles Kerguelen, 35760 Saint-Grégoire, France.

SAMRoute names the company's product line. It produces software for the quantitative analysis of risks on transport infrastructure. The current line of work describes road–rail level crossings across the French national network.

2. The founder

Fabrice Colas, founder of Oriskami SAS
Fabrice Colas, founder.

Fabrice Colas founded the company and runs the work. The fifteen years before SAMRoute split between two strands. Academic research in statistical learning and applied epidemiology came first. Production engineering of risk systems at scale came second.

2.1 Track record

PhD in statistical learning from Leiden University (2006–2009). Then postdoctoral research positions at UCLA (Los Angeles), UMC Utrecht, and Leiden University Medical Center on the human genetics of autism, schizophrenia, and rheumatoid arthritis (2010–2013). A later posting at the cardio-thoracic surgery department of CHU Rennes (2018–2019) added applied epidemio-statistical work in the clinical setting.

Full-stack engineering training at Hack Reactor (San Francisco, 2014). Between the academic and the SAMRoute years, applied risk-modelling work in production at Travix International (Amsterdam) recovered roughly €2.3M against live traffic. The same statistical methods that worked on clinical cohorts worked here on a commercial portfolio.

2.2 Selected publications

Five recent peer-reviewed papers, in decreasing date order:

  • Current results of left ventricular assist device therapy in France: the ASSIST-ICD registry. A Anselmi, V Galand, A Vincentelli, S Boule, C Dambrin, F Colas, et al. European Journal of Cardio-Thoracic Surgery 58(1):112–120 (2020). DOI: 10.1093/ejcts/ezaa055 — IF ~3.0

  • The role of rare compound heterozygous events in autism spectrum disorder. BD Lin, F Colas, IJ Nijman, et al. Translational Psychiatry 10:204 (2020). DOI: 10.1038/s41398-020-00866-7 — IF ~6.2

  • Long-term follow-up of the Shelhigh™ SuperStentless bioprosthesis aortic valve and valved conduit in a monocentric experience. F Le Bars, J Tomasi, R Belhaj Soulami, F Colas, A Anselmi, JP Verhoye. Journal of Cardiovascular Surgery (Torino) 61(6):776–783 (2020). DOI: 10.23736/S0021-9509.20.11219-9 — IF ~1.4

  • Genetic analysis of DNA methylation and gene expression levels in whole blood of healthy human subjects. KR van Eijk, S de Jong, MPM Boks, T Langeveld, F Colas, JH Veldink, et al. BMC Genomics 13:636 (2012). DOI: 10.1186/1471-2164-13-636 — IF ~3.7

  • Clinical subtypes of Parkinson's disease. SM van Rooden, F Colas, P Martínez-Martín, M Visser, D Verbaan, et al. Movement Disorders 26(1):51–58 (2011). DOI: 10.1002/mds.23346 — IF ~7.4

The fuller record is on the founder's LinkedIn profile.

2.3 Recognised R&D status

Beyond the company's own R&D credit, the founder holds a personal CIR-approved consultant agrément from the French Ministry of Research (Crédit d'Impôt Recherche). The Ministry first granted it in 2022 and renewed it in May 2025 for the 2025–2027 cycle. A parallel CII (Crédit d'Impôt Innovation) agrément runs for the same period.

The two CIR positions sit alongside the company's own filings. The Research timeline describes them in detail. Anyone can verify the consultant agrément independently through the Ministry's published registry.

3. Where we work

The company operates from the greater Rennes metropolitan area. The registered office and development premises sit in Saint-Grégoire (Ille-et-Vilaine, Brittany).

What we sell are digital assets coming out of our own production facility. Production runs on machines we operate ourselves, 24/7 connected. Cloud workloads stay scoped to the web-fronts and CDN. Trust & Security covers the residency, sub-processor, and access-control commitments that follow from this setup.

4. Reach us

For commercial enquiries, contact@samroute.com or +33 2 30 96 66 74. For privacy, GDPR, or DPA matters, legal@oriskami.com. For security or incident reports, security@samroute.com. For investor enquiries, investors@oriskami.com.